Cargando…

2564. Population Pharmacokinetics and Pharmacodynamics of Cefepime in Hospitalized Obese and Non-Obese Patients

BACKGROUND: The objectives of this study were to describe population pharmacokinetics (PK) of cefepime and to evaluate pharmacodynamics (PD) of cefepime based on population PK model with various dosing regimens through Monte Carlo simulation to optimize dosing regimens for obese patients. METHODS: H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Beomjin, Chung, Eun Kyuong, Cheatham, S Christian, Fleming, Megan R, Healy, Daniel P, Kays, Michael B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678638/ http://dx.doi.org/10.1093/ofid/ofad500.2181

Ejemplares similares

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients
por: Morrisette, Taylor, et al.
Publicado: (2019)

1547. Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion
por: Moore, Sarah E, et al.
Publicado: (2019)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

Some Pharmacodynamic Aspects of Cefepime
por: Elsayed, Mossad Gamaleddin Ahmed, et al.
Publicado: (2013)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
por: Álvarez, José C., et al.
Publicado: (2021)

1380. Effect of Absolute Body Weight on Clinical Outcomes of Obese Patients Treated with Cefepime
por: Wagner, Jamie L, et al.
Publicado: (2018)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

2564. What Predicts Journal Publication Tier and Audience Engagement in the Infectious Diseases Literature? A Review of 146 Publications
por: Cortes-Penfield, Nicolas W, et al.
Publicado: (2019)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

2564. Clinical Validation of a Commercial LAMP Test for Ruling Out Malaria in Returning Travelers: A Prospective Diagnostic Trial
por: Cheaveau, James, et al.
Publicado: (2018)

281. Mathematical modeling of corticosteroid induced secondary infection and In silico Dose exploration of Dexamethasone, Hydrocortisone
por: Kim, Dong-Hyun, et al.
Publicado: (2023)

2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies
por: Vollmer, Jannik, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
por: Veillette, John J., et al.
Publicado: (2021)

1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
por: Liu, Jiajun, et al.
Publicado: (2018)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
por: Kois, Abigail K, et al.
Publicado: (2021)

Catecholamine pharmacokinetics and pharmacodynamics in critical illness
por: Johnston, AJ, et al.
Publicado: (2003)

Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients
por: Maseda, Emilio, et al.
Publicado: (2018)

Fate of patients with slipped capital femoral epiphysis (SCFE) in later life: risk of obesity, hypothyroidism, and death in 2,564 patients with SCFE compared with 25,638 controls
por: Hailer, Yasmin D
Publicado: (2020)

2440. Weight-Adjusted Piperacillin–Tazobactam (PIP/TAZ) Therapy in Obese Patients vs. Optimized Doses in Non-obese Patients: A Retrospective Cohort Study
por: Moore, Sarah, et al.
Publicado: (2018)

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
por: Zhao, Yang, et al.
Publicado: (2020)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

2946. Comparative Pharmacokinetics and Pharmacodynamics of Cefadroxil and Cephalexin for Pediatric Musculoskeletal Infections
por: Haynes, Andrew, et al.
Publicado: (2023)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
por: Russu, Alberto, et al.
Publicado: (2016)

2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018)

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)
por: Purdy, Andrew Scott, et al.
Publicado: (2023)

1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients
por: Kalaria, Shamir N, et al.
Publicado: (2021)

A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations
por: Talha Zahid, Muhammad, et al.
Publicado: (2023)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated Pneumonia
por: Seo, Hyeonji, et al.
Publicado: (2023)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

2528. Cefepime Induced Neurotoxicity in Patients With or Without a History of Seizures
por: Baalbaki, Nadeem, et al.
Publicado: (2023)

1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients
por: Katsube, Takayuki, et al.
Publicado: (2020)

Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro
por: Schwameis, Richard, et al.
Publicado: (2008)

Influence of endotoxin induced fever on the pharmacokinetics of intramuscularly administered cefepime in rabbits
por: Goudah, Ayman, et al.
Publicado: (2006)

1594. Evaluating Clinical Outcomes of an Alternative Cefepime Dosing Regimen as Empiric Antibiotic Therapy in Hospitalized Adults with Febrile Neutropenia
por: Haiduc, Manuela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kmsbhb4cnvr1iuq6o2m7mq189q